doi: 10.3389/fcvm.2025.1657950 Received 02 July 2025 Accepted 04 September 2025 Published 25 September 2025 Volume 12 - 2025 Edited by DeLisa Fairweather, Mayo Clinic Florida, United States Reviewed by Bing Bo, Henan University, China Amogh Verma, Rama Medical College Hospital and Research Centre, India Bela Juhsz, University of Debrecen, Hungary Updates Copyright 2025 Cheng, Zhang, Si, Yin, Chen, Ru, Chu, Xiang, Liao, Ran, Zhang and Wu
C., Ward, J
Here is the key classification distinction: compounded semaglutide and compounded tirzepatide are not FDA-approved finished products
Duration varies by patient
It is like putting on armor before you head into battle rather than trying to patch things up afterward